Histone Deacetylase Inhibitors: 749 Clinical Trials, Page 4 of 75

MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas

Condition(s):Adult Grade III Lymphomatoid Granulomatosis; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Intraocular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Primary Central Nervous System Non-Hodgkin Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Adult T-cell Leukemia/Lymphoma; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Mycosis Fungoides/Sezary Syndrome; Stage IV Small Lymphocytic Lymphoma; Unspecified Adult Solid Tumor, Protocol Specific; Waldenström MacroglobulinemiaLast Updated:January 24, 2013Completed

32

Phase I Dose-finding and Preliminary Efficacy Study of the Istodax^® in Combination With Doxil^® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma

Condition(s):Lymphoma; T-Cell Lymphoma; Cutaneous LymphomaLast Updated:June 9, 2020Completed

33

Use Lay Language. HA Score to Identify Myeloma Patients Who Could Benefit From HDACi Treatment

Condition(s):Patients With Recurrent or Refractory Multiple MyelomaLast Updated:May 11, 2018Unknown status

34

Sintilimab in Combination With Chidamide in Refractory and Relapsed ENKTCL

Condition(s):Safety and EfficacyLast Updated:April 14, 2022Completed

35

Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia

Condition(s):Adult Acute Basophilic Leukemia; Adult Acute Eosinophilic Leukemia; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Blastic Phase Chronic Myelogenous Leukemia; Recurrent Adult Acute Myeloid Leukemia; Unspecified Adult Solid Tumor, Protocol SpecificLast Updated:September 19, 2013Terminated

36

LBH589 Oral in Combination With Carboplatin and Paclitaxel in Advanced Solid Tumors

Condition(s):Advanced Solid TumorsLast Updated:September 13, 2011Unknown status

37

Dietary Histone Deacetylase Inhibitors (HDAC)

Condition(s):Histone Deacetylase (HDAC) ActivityLast Updated:April 30, 2019Terminated

38

Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia

Condition(s):Acute Leukemias of Ambiguous Lineage; Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic LeukemiaLast Updated:July 17, 2014Completed

40

Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation

Condition(s):Granulin MutationLast Updated:March 23, 2016Unknown status

Histone Deacetylase Inhibitors: 749 Clinical Trials, Page 4 of 75

MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas

Phase I Dose-finding and Preliminary Efficacy Study of the Istodax^® in Combination With Doxil^® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma

Use Lay Language. HA Score to Identify Myeloma Patients Who Could Benefit From HDACi Treatment

Sintilimab in Combination With Chidamide in Refractory and Relapsed ENKTCL

Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia

LBH589 Oral in Combination With Carboplatin and Paclitaxel in Advanced Solid Tumors

Dietary Histone Deacetylase Inhibitors (HDAC)

Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia

Sintilimab in Combination With Chidamide in Refractory and Relapsed AITL

Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation

Clinical Trials by Category

Clinical Trials Alphabetically

About

MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas

Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma

Use Lay Language. HA Score to Identify Myeloma Patients Who Could Benefit From HDACi Treatment

Sintilimab in Combination With Chidamide in Refractory and Relapsed ENKTCL

Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia

LBH589 Oral in Combination With Carboplatin and Paclitaxel in Advanced Solid Tumors

Dietary Histone Deacetylase Inhibitors (HDAC)

Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia

Sintilimab in Combination With Chidamide in Refractory and Relapsed AITL

Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation

Clinical Trials by Category

Clinical Trials Alphabetically

About

Phase I Dose-finding and Preliminary Efficacy Study of the Istodax^® in Combination With Doxil^® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma